CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
Design and rationale of the EMPEROR trials of, empagliflozin 10 mg once daily, in patients with chronic heart failure with reduced ejection fraction (EMPEROR-Reduced) or preserved ejection fraction (EMPEROR-Preserved)
DOI 10.1055/s-0039-1688298
Bibliografische Angaben
Nachweis in CareLit
Autor:innenS Anker, F Zannad, J Butler, G Filippatos, A Salsali, K Kimura, J Schnee, C Zeller, S Pocock, J George, M Brueckmann, M Packer
ZeitschriftDiabetologie und Stoffwechsel
AusgabeS 01 S 01/2019
Jahrgang / SeitenJg. 14
Kernaussage aus der Literatur
Abstract-Vorschau
Design and rationale of the EMPEROR trials of, empagliflozin 10 mg once daily, in patients with chronic heart failure with reduced ejection fraction (EMPEROR-Reduced) or preserved ejection fraction (EMPEROR-Preserved)
Zitieren
Zitierempfehlung
S Anker, F Zannad, J Butler, G Filippatos, A Salsali, K Kimura, J Schnee, C Zeller, S Pocock, J George, M Brueckmann, M Packer (2019) Design and rationale of the EMPEROR trials of, empagliflozin 10 mg once daily, in patients with chronic heart failure with reduced ejection fraction (EMPEROR-Reduced) or preserved ejection fraction (EMPEROR-Preserved). Diabetologie und Stoffwechsel, 14 (S 01 S 01). https://doi.org/10.1055/s-0039-1688298
Mit CareLit weiterarbeiten